Food and Drug Administration (FDA) Disclosure:

The statements in this forum have not been evaluated by the Food and Drug Administration and are generated by non-professional writers. Any products described are not intended to diagnose, treat, cure, or prevent any disease.

Website Disclosure:

This forum contains general information about diet, health and nutrition. The information is not advice and is not a substitute for advice from a healthcare professional.

Cannabinoids are being used in clinical trials in the US and other countries for indications other than the direct treatment of cancer.

Discussion in 'Medical Marijuana Usage and Applications' started by jainaG, Aug 13, 2015.

  1. ..."You can find out the details about these trials by visiting http://www.cancer.gov/clinicaltrialsOpens new window or http://apps.who.int/trialsearch/Opens new window


    http://www.cpmc.org/professionals/research/programs/science/cannabidiolarticles.html



    Sean D. McAllister, Ph.D.
    Email: Mcallis@cpmcri.org

    Pierre Desprez, Ph.D.
    Email: DesprePY@cpmcri.org

    Publications
    McAllister
    SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C,
    Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY.
    Pathways mediating the effects of cannabidiol on the reduction of breast
    cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat. 2011 Aug;129(1):37-47. Epub 2010 Sep 22.

    McAllister
    SD, Christian RT, Horowitz MP, Garcia A, Desprez P. Cannabidiol as a
    novel inhibitor of Id-1 gene expression in aggressive breast cancer
    cells. Molecular Cancer Therapeutics 6, 2921-2927, November 1,
    2007.Opens new window

    News Interview
    Sean
    McAllister and Pierre Desprez discussed their recently published
    findings on cannabidiol inhibiting breast cancer progression in culture
    on BBC News/Health and in the San Francisco Chronicle .
    Use the key word cannabinoids. These sites are also a wonderful
    resource for finding additional novel trials that focus on treating
    cancer.

    At this point, there is no clinical evidence
    demonstrating cannabiniods/cannabis can slow cancer progression but the
    preclinical data in culture and in mouse models of cancer show the
    compounds could slow the progression of many types of cancer. There are
    however multiple clinical studies with cancer patients that show that
    cannabinoid compounds and cannabis can be used palliatively to reduce
    nausea and pain, and increase appetite.

    In preclinical models of
    brain cancer, cannabinoids were most efficacious when given in
    combination with temozolomide-a common first-line agent used to target
    brain cancer. Based on the data, it would be expected that cannabinoids
    would need to be combined with a first-line agent in order to see the
    most efficacy in a clinical setting. Recent publications using
    preclinical models suggest this type of enhancement of drug activity
    occurs in other cancers when cannabinoids are combined with first-line
    agents.

    We targeted breast cancer cells that expressed high
    amounts of the protein Id-1. CBD is highly effective at turning off
    this specific gene that controls breast cancer metastasis. In addition
    to directly controlling cancer metastasis, turning off Id-1 has also
    lead to enhanced activity of first-line agents in preclinical models of
    cancer.
    References
    Soroceanu L, Murase R, Limb
    C...Desprez PY, McAllister SD. Id-1 is a key transcriptional regulator
    of glioblastoma aggressiveness and a novel therapeutic target. Cancer
    Res 2013;73(5):1559-69. doi: 10.1158/0008-5472.CAN-12-1943. Epub 2012
    Dec 13.


    Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as
    antitumour agents. Nature Reviews Cancer 12, 436-444 (June 2012) |
    doi:10.1038/nrc3247Opens new window.

    Carter GT, Flanagan AM, Earleywine M, Abrams DI, Aggarwal SK, Grinspoon
    L. Cannabis in palliative medicine: improving care and reducing
    opioid-related morbidity. Am J Hosp Palliat Care 2011;28:297-303Opens new window.

    Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical
    therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10:90-103Opens new window.


    McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY.
    Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive
    breast cancer cells. Mol Cancer Ther 2007;6:2921-7Opens new window.


    McAllister SD, Murase R, Christian RT, et al. Pathways mediating the
    effects of cannabidiol on the reduction of breast cancer cell
    proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011;129:37-47Opens new window.


    Hu H, Han HY, Wang YL, et al. The role of Id-1 in chemosensitivity and
    epirubicin-induced apoptosis in bladder cancer cells. Oncol Rep
    2009;21:1053-9Opens new window.


    Ponz-Sarvise M, Nguewa PA, Pajares MJ, et al. Inhibitor of
    differentiation-1 as a novel prognostic factor in NSCLC patients with
    adenocarcinoma histology and its potential contribution to therapy
    resistance. Clin Cancer Res 2011;17:4155-66Opens new window.

    Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells


    \t\t\t\t\t\t\t\t\t

    \t\t\t\t\t\t\t\t\t
    \t\t\t\t\t\t\t\t


    \t\t\t\t\t\t\t

    \t\t\t\t\t\t\t\t\t\t\t\t\t\t
    \t\t\t\t\t\t\t\t
    \t\t\t\t\t\t\t

    \t\t\t\t\t\t\t


    \t\t\t\t\t\t

    \t\t\t\t\t\t
    \t\t\t\t\t\t\t\t
    \t\t\t\t\t\t
    \t\t\t\t\t\t\t\t\t
    \t\t\t\t\t\t\t\t\t\t





     
Loading...

Share This Page